← All drugs Report issue

bgb-a1217

mAbexperimental

Clinical trial activity

14 trials · 4 clinical orgs · 0 marketing orgs

Phase 1

2

Phase 2

13

Phase 3

3

Phase 4

0

Earliest trial started Aug 12, 2019 (NCT04047862)

Timeline

2010s

Jan 1, 2019
Earliest Phase 1 Sponsor(trial)

2020s

Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Jan 1, 2021
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

T-cell immunoreceptor with Ig and ITIM domainsANTAGONIST
TIGIT antagonist
- T-cell immunoreceptor with Ig and ITIM domains (TIGIT) ↗
T-cell immunoreceptor with Ig and ITIM domainsINHIBITOR
T-cell immunoreceptor with Ig and ITIM domains inhibitor
- T-cell immunoreceptor with Ig and ITIM domains (TIGIT) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL4650411 ↗

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05809895	Phase 2	Sep 15, 2023	Novartis
NCT05791097	Phase 3	Jul 28, 2023	Novartis
NCT05577702	Phase 2	Dec 31, 2022	BeOne Medicines
NCT05267054	Phase 1/Phase 2 (Phase 2)	Apr 25, 2022	BeOne Medicines
NCT05014815	Phase 2	Nov 30, 2021	BeOne Medicines
NCT05019677	Phase 2	Sep 1, 2021	Fudan University
NCT05023109	Phase 2	Sep 1, 2021	Fudan University
NCT04948697	Phase 2	Aug 20, 2021	BeOne Medicines
NCT04952597	Phase 2	Jul 15, 2021	BeOne Medicines
NCT04866017	Phase 3	Jun 17, 2021	BeOne Medicines
NCT04746924	Phase 3	Jun 8, 2021	BeOne Medicines
NCT04732494	Phase 2	Mar 31, 2021	BeOne Medicines
NCT04693234	Phase 2	Jan 25, 2021	BeOne Medicines
NCT04047862	Phase 1	Aug 12, 2019	BeOne Medicines, Linear Clinical Research

Showing 14 of 14 trials

Page 1 / 1

Organizations

Research & Development (4)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
BeOne Medicines	For profit	10	10	3	2019
Fudan University	Academic/Hospital	2	2	1	2021
Novartis	For profit	2	2	2	2023
Linear Clinical Research	For profit	1	0	1	2019

4 organizations

Page 1 / 1